Kaveri Pohlman
Stock Analyst at Clear Street
(0.45)
# 4,138
Out of 5,005 analysts
25
Total ratings
25%
Success rate
-27.72%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Kaveri Pohlman
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| VTYX Ventyx Biosciences | Initiates: Buy | $11 | $3.60 | +205.56% | 1 | Oct 1, 2025 | |
| RAPT RAPT Therapeutics | Maintains: Buy | $24 → $41 | $30.14 | +36.03% | 1 | Sep 30, 2025 | |
| ORKA Oruka Therapeutics | Maintains: Buy | $46 | $19.79 | +132.44% | 1 | Sep 17, 2025 | |
| AVBP ArriVent BioPharma | Initiates: Buy | $32 | $19.84 | +61.29% | 1 | Jun 25, 2025 | |
| MGNX MacroGenics | Downgrades: Neutral | n/a | $1.78 | - | 4 | Aug 1, 2024 | |
| GMAB Genmab | Maintains: Buy | $46 → $47 | $33.56 | +40.05% | 3 | Jun 27, 2024 | |
| CGEM Cullinan Therapeutics | Maintains: Buy | $20 → $30 | $5.90 | +408.47% | 2 | Apr 17, 2024 | |
| XNCR Xencor | Maintains: Buy | $56 → $38 | $11.77 | +222.85% | 1 | Apr 16, 2024 | |
| NUVB Nuvation Bio | Upgrades: Buy | $5 | $3.71 | +34.77% | 2 | Mar 26, 2024 | |
| JANX Janux Therapeutics | Initiates: Buy | $62 | $24.00 | +158.33% | 1 | Mar 21, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $8 | $2.57 | +211.28% | 1 | Feb 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $27 | $40.09 | -32.65% | 1 | Dec 19, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $70 | $13.35 | +424.34% | 1 | Aug 23, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $12 | $2.35 | +410.64% | 1 | Aug 31, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $16 → $8 | $3.30 | +142.42% | 2 | Jul 7, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $12,320 → $4,928 | $5.63 | +87,431.08% | 2 | Feb 9, 2022 |
Ventyx Biosciences
Oct 1, 2025
Initiates: Buy
Price Target: $11
Current: $3.60
Upside: +205.56%
RAPT Therapeutics
Sep 30, 2025
Maintains: Buy
Price Target: $24 → $41
Current: $30.14
Upside: +36.03%
Oruka Therapeutics
Sep 17, 2025
Maintains: Buy
Price Target: $46
Current: $19.79
Upside: +132.44%
ArriVent BioPharma
Jun 25, 2025
Initiates: Buy
Price Target: $32
Current: $19.84
Upside: +61.29%
MacroGenics
Aug 1, 2024
Downgrades: Neutral
Price Target: n/a
Current: $1.78
Upside: -
Genmab
Jun 27, 2024
Maintains: Buy
Price Target: $46 → $47
Current: $33.56
Upside: +40.05%
Cullinan Therapeutics
Apr 17, 2024
Maintains: Buy
Price Target: $20 → $30
Current: $5.90
Upside: +408.47%
Xencor
Apr 16, 2024
Maintains: Buy
Price Target: $56 → $38
Current: $11.77
Upside: +222.85%
Nuvation Bio
Mar 26, 2024
Upgrades: Buy
Price Target: $5
Current: $3.71
Upside: +34.77%
Janux Therapeutics
Mar 21, 2024
Initiates: Buy
Price Target: $62
Current: $24.00
Upside: +158.33%
Feb 9, 2024
Initiates: Buy
Price Target: $8
Current: $2.57
Upside: +211.28%
Dec 19, 2023
Initiates: Buy
Price Target: $27
Current: $40.09
Upside: -32.65%
Aug 23, 2023
Reiterates: Buy
Price Target: $70
Current: $13.35
Upside: +424.34%
Aug 31, 2022
Initiates: Buy
Price Target: $12
Current: $2.35
Upside: +410.64%
Jul 7, 2022
Maintains: Buy
Price Target: $16 → $8
Current: $3.30
Upside: +142.42%
Feb 9, 2022
Maintains: Buy
Price Target: $12,320 → $4,928
Current: $5.63
Upside: +87,431.08%